After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Yahoo Finance discussed the stock recently as it posted AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
CERE belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $42.24 and fluctuated between $42.41 as its day high and $42.21 as its day low. The current market capitalization of Cerevel Therapeutics Holdings Inc is $7.67B. A total of 1.75 million shares were traded on the day, compared to an average of 1.83M shares.
In the most recent transaction, COLES N ANTHONY sold 50,000 shares of CERE for 41.01 per share on Mar 04 ’24. After the transaction, the Director now owns 15,638 company shares. In a previous transaction on Feb 29 ’24, COLES N ANTHONY sold 50,000 shares at 41.16 per share. CERE shares that Director owns now total 15,638.
Among the insiders who sold shares, COLES N ANTHONY disposed of 2,506 shares on Feb 07 ’24 at a per-share price of $41.54. This resulted in the Director holding 15,638 shares of CERE after the transaction. In another insider transaction, Renger John sold 2,161 shares at $41.54 per share on Feb 07 ’24. Company shares held by the Chief Scientific Officer now total 6,370.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, CERE has a high of $43.59 and a low of $19.59.
As of this writing, CERE has an earnings estimate of -$0.61 per share for the current quarter. EPS was calculated based on a consensus of 7 estimates, with a high estimate of -$0.49 per share and a lower estimate of -$0.76. The company reported an EPS of -$0.61 in the last quarter, which was 3.20% higher than expectations of -$0.63.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. CERE’s latest balance sheet shows that the firm has $565.69M in Cash & Short Term Investments as of fiscal 2021. There were $36.55M in debt and $42.54M in liabilities at the time. Its Book Value Per Share was $3.71, while its Total Shareholder’s Equity was $578.73M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CERE is Buy with a score of 3.36.
